1National Hospital Organization Kyoto Medical Center, Kyoto, Japan; 2START, Japan Science and Technology Agency (JST), Tokyo, Japan.
3Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Miyagi, Japan.
Georgian Med News. 2023 Jul-Aug(340-341):37-46.
Certain mutant strains of SARS-CoV-2 are known to spread widely among humans, including the receptor binding domain (RBD) mutant, Y453F, from farmed minks, and the RBD mutant, N501Y, a mutation common to three major SARS-CoV-2 subvariants (B.1.1.7, B.1.351, and B.1.1.248) and omicron type SARS-CoV-2 BQ.1.1 and XBB.1.16 subvariants. We investigated the characteristics of the RBD mutants, Y453F and N501Y, using three-dimensional structural analysis. We also investigated the effect of Y453F, N501Y or the mutants of RBD of omicron type SARS-CoV-2 BQ.1.1 and XBB.1.16 subvariants on neutralizing antibodies in serum derived from individuals including children (aged 5-11 years) inoculated with mRNA based COVID-19 vaccine (BNT162b2: Pfizer/BioNTech) or COVID-19-positive patients or children (aged 5-11 years) after vaccination with BNT162b2. Our results suggest that SARS-CoV-2 subspecies with the RBD mutations Y453F or N501Y partially escaped detection by 4 neutralizing monoclonal antibodies and 21 neutralizing antibodies in serums derived from COVID-19-positive patients. The significantly low antibody titer of children against Omicron type SARS-CoV-2 BQ.1.1 subvariant and XBB.1.16 subvariant in Japan. Infection with SARS-CoV-2 subspecies that causes serious symptoms in humans may spread globally. In particular, since the antibody titer against the omicron type is low in children (aged 5-11 years) who have been vaccinated with conventional vaccines, therefore it is important for children to receive vaccines specific for the omicron type.
已知某些 SARS-CoV-2 的突变株在人类中广泛传播，包括来自养殖水貂的受体结合域（RBD）突变株 Y453F，以及 RBD 突变株 N501Y，该突变株是三种主要 SARS-CoV-2 亚变种（B.1.1.7、B.1.351 和 B.1.1.248）和 omicron 型 SARS-CoV-2 BQ.1.1 和 XBB.1.16 亚变种的共同突变。我们使用三维结构分析研究了 RBD 突变株 Y453F 和 N501Y 的特征。我们还研究了 omicron 型 SARS-CoV-2 BQ.1.1 和 XBB.1.16 亚变种的 RBD 突变株 Y453F、N501Y 或突变株对来自接种了基于 mRNA 的 COVID-19 疫苗（BNT162b2：辉瑞/BioNTech）的个体（包括儿童[5-11 岁]）、COVID-19 阳性患者或接种 BNT162b2 后的儿童（5-11 岁）的血清中的中和抗体的影响。我们的结果表明，具有 RBD 突变 Y453F 或 N501Y 的 SARS-CoV-2 亚种部分逃避了来自 COVID-19 阳性患者的 4 种中和单克隆抗体和 21 种中和抗体的检测。在日本，儿童对 omicron 型 SARS-CoV-2 BQ.1.1 亚变种和 XBB.1.16 亚变种的抗体滴度显著较低。引起人类严重症状的 SARS-CoV-2 亚种可能会在全球范围内传播。特别是，由于常规疫苗接种的儿童（5-11 岁）对 omicron 型的抗体滴度较低，因此为儿童接种针对 omicron 型的疫苗非常重要。
